RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | £3 | £2 | £1 | £1 |
| % Growth | 69.9% | 9.1% | 75.9% | – |
| Cost of Goods Sold | £1 | £0 | £0 | £0 |
| Gross Profit | £2 | £1 | £1 | £0 |
| % Margin | 73.5% | 71.6% | 78.7% | 54.3% |
| R&D Expenses | £0 | £0 | £1 | £0 |
| G&A Expenses | £2 | £2 | -£1 | £2 |
| SG&A Expenses | £2 | £2 | -£1 | £2 |
| Sales & Mktg Exp. | £0 | £0 | £0 | -£0 |
| Other Operating Expenses | £0 | £0 | £1 | £0 |
| Operating Expenses | £3 | £2 | £2 | £2 |
| Operating Income | -£1 | -£0 | -£1 | -£1 |
| % Margin | -21.8% | -27.9% | -41.3% | -176.8% |
| Other Income/Exp. Net | -£0 | £1 | -£0 | -£0 |
| Pre-Tax Income | -£1 | £1 | -£1 | -£1 |
| Tax Expense | £0 | -£0 | -£0 | -£0 |
| Net Income | -£1 | £1 | -£0 | -£1 |
| % Margin | -24.5% | 41.7% | -30.8% | -127.2% |
| EPS | -0.01 | 0.019 | -0.013 | -0.046 |
| % Growth | -154% | 247.7% | 71.9% | – |
| EPS Diluted | -0.01 | 0.019 | -0.013 | -0.046 |
| Weighted Avg Shares Out | 62 | 34 | 34 | 22 |
| Weighted Avg Shares Out Dil | 62 | 34 | 34 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | £1 | -£0 | -£1 |
| % Margin | -17.1% | 55.3% | -28.5% | -148% |